Silencing of CSN5 gene expression using interfering RNA

US8227443B2 · kind B2 · utility

Assignees

• Protiva Biotherapeutics, Inc. · CA
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Ian MacLachlan · Vancouver, CA
• Adam Judge · Vancouver, CA
• Snorri S. Thorgeirsson · Bethesda, US
• Yun-Han Lee · Hengshan, TW

Key dates

• Filing date: Oct 13, 2010
• Grant date: Jul 24, 2012
• Expiry date: Oct 13, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compositions comprising nucleic acids that target CSN5 gene expression and methods of using such compositions to silence CSN5 gene expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence CSN5 gene expression and methods of use thereof, e.g., for treating cell proliferative disorders such as cancer. The present invention also provides nucleic acid-lipid particles that target CSN5 gene expression comprising an interfering RNA molecule, a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that inhibits aggregation of particles.